Core Points - Rosen Law Firm is reminding investors who purchased Akero Therapeutics, Inc. common stock between September 13, 2022, and October 9, 2023, of the June 25, 2024, lead plaintiff deadline for a class action lawsuit [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must act by the specified deadline to serve as lead plaintiff [1] Case Details - The lawsuit alleges that Akero made false and misleading statements regarding the SYMMETRY study, which tested its lead product candidate, efruxifermin (EFX), in patients with Non-alcoholic Steatohepatitis (NASH) induced cirrhosis [3] - Key allegations include that approximately 20% of patients in the SYMMETRY study had cryptogenic cirrhosis and did not have definitive NASH at baseline [3] - The lawsuit claims that the results from these patients were improperly included in the study, which could materially influence the study's outcomes and increase the risk of failing to meet its primary endpoint [3] - It is also alleged that Akero did not align the study with U.S. FDA guidance, failing to rule out other potential causes of cirrhosis [3] - The misrepresentation of the SYMMETRY trial's nature and its implications for EFX's commercial viability is central to the claims made in the lawsuit [3]

SAN DIEGO, June 23, 2024 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Akero Therapeutics, Inc. (NASDAQ: AKRO) common stock between September 13, 2022 and October 9, 2023, all dates inclusive (the “Class Period”), have until this Tuesday, June 25, 2024 to seek appointment as lead plaintiff. Captioned Klobus v. Akero Therapeutics, Inc., No. 3:24-cv-02534 (N.D. Cal.), the Akero class action lawsuit charges Akero and certain of its top executive officers with ...

RADNOR, Pa., June 23, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) on behalf of investors who purchased or acquired Akero common stock between September 13, 2022 and October 9, 2023, inclusive (the “Class Period”).. The action charges Akero with violations of ...

NEW YORK, June 22, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action lawsuit on behalf of all purchasers of common stock of Akero Therapeutics, Inc. (NASDAQ: AKRO) between September 13, 2022 and October 9, 2023. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by June 25, 2024.To join the Akero class action, go to https://rosenlegal.com/submit-form/?case_id=24557 or call Phill ...

NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Akero Therapeutics, Inc. (NASDAQ: AKRO) between September 13, 2022 and October 9, 2023, both dates inclusive (the “Class Period”), of the important June 25, 2024 lead plaintiff deadline. SO WHAT: If you purchased Akero common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arra ...

LOS ANGELES, June 20, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming June 25, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Akero Therapeutics, Inc. (“Akero” or the “Company”) (NASDAQ: AKRO) common stock between September 13, 2022 and October 9, 2023, inclusive (the “Class Period”). If you suffered a loss on your Akero investments or would like to inquire about potentially pur ...

SAN DIEGO, June 20, 2024 (GLOBE NEWSWIRE) --  The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Akero Therapeutics, Inc. (NASDAQ: AKRO) common stock between September 13, 2022 and October 9, 2023, all dates inclusive (the “Class Period”), have until June 25, 2024 to seek appointment as lead plaintiff. Captioned Klobus v. Akero Therapeutics, Inc., No. 3:24-cv-02534 (N.D. Cal.), the Akero class action lawsuit charges Akero and certain of its top executive officers with violations o ...

LOS ANGELES, June 18, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Akero Therapeutics, Inc. (“Akero” or “the Company”) (NASDAQ: AKRO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company’s securities between September 13, 2022 and October 9, 2023, inclusive (the “Clas ...

Core Viewpoint - Akero Therapeutics, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims centered around misleading statements regarding its clinical trials for the treatment of nonalcoholic steatohepatitis (NASH) [1][3][4]. Company Overview - Akero Therapeutics is a clinical stage biopharmaceutical company focused on developing efruxifermin (EFX) as a treatment for NASH, a serious liver disease [2]. Allegations of the Lawsuit - The lawsuit alleges that Akero made false or misleading statements and failed to disclose critical information during the class period, including: - Approximately 20% of patients in the SYMMETRY study had cryptogenic cirrhosis and did not have definitive NASH at baseline [3]. - The inclusion of these patients materially influenced the study's potential results and increased the risk of failing to meet primary endpoints [3]. - The study did not align with FDA guidance for testing drugs in NASH cirrhotics, as potential causes of cirrhosis other than NASH were not ruled out [3]. Impact on Stock Price - Following the disclosure of the study's 36-week results on October 10, 2023, Akero's stock price plummeted nearly 70%, leading to substantial losses for investors [4]. Legal Process - Investors who purchased Akero common stock during the class period have until June 25, 2024, to seek appointment as lead plaintiff in the class action lawsuit [1][5]. Firm Background - Robbins Geller Rudman & Dowd LLP is a leading firm in prosecuting investor class actions, having recovered over $1.75 billion for investors in 2022 alone [6][7].

NEW YORK, June 16, 2024 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Akero Therapeutics, Inc. (NASDAQ: AKRO) between September 13, 2022 and October 9, 2023, both dates inclusive (the “Class Period”), shareholders who want to serve as lead plaintiff for the class must file their motions with the court by August 12, 2024. If you purchased Akero common stock during the Class Period you may be entitled to compensation without payment of any out of ...